Last updated: April 11, 2026
What is NDC 00486-1111?
NDC 00486-1111 corresponds to Vials of Lovenox (enoxaparin sodium), a low molecular weight heparin (LMWH) used for prophylaxis and treatment of thromboembolic events. It has multiple indications, including deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndromes.
Market Overview
Market Demand
The global enoxaparin market was valued at approximately USD 8.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% through 2027.
| Segment |
Key Drivers |
Challenges |
| Hospital procurement |
Growing prevalence of venous thromboembolism (VTE), elective surgeries |
Patent expiration, biosimilar entry |
| Outpatient clinics |
Increased use in outpatient anticoagulation therapy |
Price competition from generics |
| Direct-to-Consumer |
Patient awareness, self-injection programs |
Cost, insurance coverage |
Major players include Sanofi (originator product), Teva, Sandoz, and Mylan, which are pursuing biosimilar development. The entry of biosimilars is expected to intensify pricing pressures.
Geographical Trends
North America dominates, accounting for approximately 50% of market share in 2022, driven by high healthcare spending and advanced hospital infrastructure. Europe follows, with increasing adoption due to revised clinical guidelines. Emerging markets, including China and India, present growth opportunities due to rising patient populations and expanding healthcare access.
Competitive Landscape
| Company |
Product Name |
Market Position |
Focus Areas |
| Sanofi |
Lovenox (originator) |
Market leader |
Patent extensions, new formulations |
| Teva |
Enoxaparin biosimilar |
Second-largest |
Cost leadership, biosimilars |
| Sandoz |
Binocrit |
Biosimilar |
Price competitiveness |
| Mylan (now part of Viatris) |
Mylan enoxaparin |
Biosimilar |
Price, availability |
Patent expiration of Lovenox occurred in 2019 in the U.S., opening the market for biosimilar entries. Biosimilar products are priced 15-30% lower than the originator.
Price Analysis and Projections
Current Pricing
| Region |
Average Wholesale Price (AWP) for a 100 mg vial |
Notes |
| United States |
USD 150–180 |
Brand vs biosimilar variance |
| Europe |
EUR 100–130 (~USD 110–140) |
Price controls, rebates |
| Asia |
USD 80–120 |
Variability by country |
Price Trends
From 2019 onward, biosimilars introduced in the U.S. and Europe have driven prices down by 20–30%. The originator's list price has stabilized but faces significant discounting in tenders and healthcare systems.
Future Price Projections (2023–2027)
| Year |
Expected Price Range (USD per 100 mg vial) |
Factors Impacting Price |
| 2023 |
USD 140–180 |
Biosimilar competition |
| 2024 |
USD 130–170 |
Market penetration increases |
| 2025 |
USD 120–160 |
Further biosimilar approvals |
| 2026 |
USD 110–150 |
Price pressure intensifies |
| 2027 |
USD 100–140 |
Market stabilization |
Prices for biosimilars are anticipated to reach 50–70% of the originator’s list price by 2027, depending on regional market access.
Regulatory and Policy Impact
- US: Biosimilar approval pathway established under the Biologics Price Competition and Innovation Act (BPCI), enacted in 2009.
- Europe: EMA approves biosimilars with strict interchangeability assessments; price discounts mandated.
- Emerging Markets: Regulatory landscapes vary; large-scale tenders favor low-cost biosimilars.
Government policies favor biosimilar uptake to reduce healthcare costs, potentially lowering prices further.
Investment and R&D Outlook
- R&D investments focus on enhanced formulations, alternative delivery methods, and biosimilar development.
- Clinical trials emphasize equivalence, bioavailability, and safety profiles of biosimilars.
- Several biosimilar candidates have received approval in Europe and are under review in the US.
Key Takeaways
- The enoxaparin market faces pricing pressures from biosimilar competition, especially in North America and Europe.
- Prices for biosimilars are expected to decrease 30–50% over the next five years.
- Patent expirations, regulatory policies, and manufacturing advances will influence market dynamics.
- Emerging markets present growth opportunities due to increasing healthcare access but face regulatory variability.
- R&D efforts are concentrated on biosimilar approval processes, with incremental improvements in bioavailability and administration.
FAQs
1. When will biosimilars for enoxaparin reach price parity with the originator?
Expected around 2025–2026, with prices reaching approximately 50–70% of the originator market price.
2. How significant is biosimilar entry to the overall enoxaparin market?
Biosimilars account for an increasing share; in 2022, they held approximately 35% of the market, projected to surpass 50% by 2027.
3. What regional factors most influence price variations?
Regulatory frameworks, reimbursement policies, and competitive tenders significantly impact regional prices.
4. Are there specific biosimilar candidates expected to dominate?
Teva’s enoxaparin biosimilar is FDA approved; other approved biosimilars are Sandoz’s and Mylan’s products with increasing market access.
5. What are the key regulatory challenges for biosimilar approval?
Proving biosimilarity through extensive clinical trials, ensuring interchangeability, and navigating regional regulatory pathways.
References
- Market Watch. (2023). Global low molecular weight heparins market forecast.
- FDA. (2022). Biologics Price Competition and Innovation Act (BPCI).
- European Medicines Agency. (2022). Biosimilar medicines overview.
- IQVIA. (2022). Enoxaparin market analysis report.
- WHO. (2023). Global biosimilars guidelines.
